Alumis (ALMS) Stock Fair Value Moves Lower After Mixed Analyst Views On LUMUS
Alumis (ALMS) has seen its fair value estimate reduced to US$27.38 from US$32.13, a 15% decrease, following mixed analyst reactions to its LUMUS systemic lupus erythematosus study. While some analysts maintain positive ratings, citing potential in psoriasis and neurology, others have turned neutral due to regulatory uncertainty and execution risks. This adjustment reflects a shifting outlook for the company's pipeline and financial projections.
Alumis reports strong Phase 3 data for envudeucitinib in psoriasis, plans NDA submission in Q4 2026
Alumis Inc. announced positive Phase 3 clinical trial results for envudeucitinib in moderate-to-severe plaque psoriasis, demonstrating rapid and lasting improvements. The company plans to submit a New Drug Application (NDA) to the FDA in Q4 2026. Additionally, Alumis reported mixed results for envudeucitinib in systemic lupus erythematosus (SLE) but found promising responses in a specific patient subgroup, and is financially stable with $431.3 million in cash.
Revenue fell to $1.91M as Alumis (ALMS) narrowed its quarterly loss.
Alumis Inc. (ALMS) reported a narrowed net loss of $94.9 million for Q3 2026, down from $110.8 million in Q3 2025, despite a slight decrease in revenue to $1.907 million. The company provided updates on its envudeucitinib program, including promising Phase 3 data for plaque psoriasis and plans for an NDA submission in Q4 2026, while also announcing that its Phase 2b SLE trial did not meet primary endpoints in the overall population but showed robust responses in a prespecified subgroup. Alumis projects its current cash and marketable securities of $431.3 million will fund operations into Q4 2027.
Alumis Inc. (NASDAQ:ALMS) Stock Has Consensus Target Price of $33.27 According to Brokerages
Alumis Inc. (NASDAQ:ALMS) has a "Moderate Buy" consensus rating from fourteen research firms, with an average 12-month price target of $33.27. Despite positive ratings, some brokerages like Oppenheimer and Morgan Stanley have lowered their price objectives. The company recently missed analysts' estimates for quarterly EPS and revenue, and its stock has fallen below its 50-day and 200-day moving averages.
Technical Reactions to ALMS Trends in Macro Strategies
This report from Stock Traders Daily provides technical analysis and trading strategies for Alumis Inc. (NASDAQ: ALMS). It identifies weak near-term sentiment and elevated downside risk, leading to the generation of three distinct AI-powered trading strategies: Position Trading (LONG), Momentum Breakout (BREAKOUT), and Risk Hedging (SHORT). The analysis includes key findings, signal strengths across different time horizons, and specific entry, target, and stop levels for each strategy.
Form 4 Alumis Inc: Sanam Pangali (CLO) For: 2 November By Investing.com
This article reports on a Form 4 filing for Alumis Inc., indicating an insider transaction by Sanam Pangali, the Chief Legal Officer (CLO), on November 2nd. Form 4 filings are regulatory documents that disclose changes in the beneficial ownership of a company's securities by its directors, officers, and principal stockholders. The article is a brief notification of this filing.
Required tax sale: Alumis (ALMS) executive sells 623 shares, not at his discretion.
Mark Christopher Bradley, Chief Development Officer of Alumis Inc. (ALMS), sold 623 shares on November 2, 2026, at a weighted average price of $6.52 per share. This sale was a "sell-to-cover" transaction, mandated by the issuer's policy to satisfy tax obligations related to the vesting of restricted stock units, and was not a discretionary decision by Bradley. Following the transaction, Bradley directly holds 47,910 shares of common stock.
Alumis CDO Mark Christopher Bradley Executes Sell-to-Cover of 623 Shares
Mark Christopher Bradley, Chief Development Officer of Alumis Inc., completed a sell-to-cover transaction on November 2, 2026, involving 623 shares of Alumis common stock. This sale was mandated by company policy to cover tax liabilities from previously granted RSUs and was not a discretionary decision. Following the transaction, Bradley directly holds 47,910 shares and indirectly holds an additional 40,052 shares through two GRAT trusts.
Alumis Inc. (ALMS) Seasonal Returns Chart - Yahoo Finance
The article provides the seasonal returns chart for Alumis Inc. (ALMS) on Yahoo Finance. It displays the stock's performance, showing a closing price of $6.73 with a -2.32% change on October 30, 2026. The page includes historical seasonality data, specifically average monthly price returns from 2024-2026, and various other financial metrics for ALMS.
Alumis Inc. Estimates – NASDAQ:ALMS
This page on TradingView provides financial estimates and data for Alumis Inc. (NASDAQ: ALMS). Users can explore reported financial data and analyst estimates across income statements, balance sheets, cash flow statements, and valuation metrics, as well as compare actual results with average, high, and low estimates. The platform emphasizes that this information is not investment advice.
Alumis reports sustained scalp and itch improvements with envudeucitinib ahead of filing
Alumis Inc. reported positive Phase III data for its oral TYK2 inhibitor, envudeucitinib (ESK-001), showing sustained scalp clearance, itch reduction, and quality-of-life improvements in adults with moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application (NDA) in Q4 2026, despite a competitive landscape in the TYK2 inhibitor class and a prior setback in a lupus trial.
Alumis Inc. (ALMS) Stock Price, News, Quote & History
Alumis Inc. (ALMS) stock closed at $6.56, down 7.08% on October 13, 2026, with an after-hours price of $6.56. The clinical-stage biopharmaceutical company focuses on autoimmune disorder treatments, including envudeucitinib for psoriasis and lupus, and has a 1-year target estimate of $31.12 despite recent analyst downgrades.
Alumis presents new psoriasis drug data, plans late 2026 filing
Alumis Inc. announced positive Phase 3 clinical trial results for its new psoriasis drug, envudeucitinib, showing significant skin clearance and itch reduction in patients with moderate-to-severe plaque psoriasis. The company plans to submit a New Drug Application for the drug in the fourth quarter of 2026. The oral TYK2 inhibitor was generally well-tolerated with no new safety signals observed during the trials.
Alumis reports 54% complete skin clearance
Alumis (NASDAQ:ALMS) announced positive Phase 3 ONWARD data for its drug envudeucitinib, showing 54% complete skin clearance at Week 48 in patients with moderate-to-severe plaque psoriasis. The data also indicated sustained improvements in scalp skin clearance, itch reduction, and patient quality of life. The company plans to submit a new drug application for envudeucitinib in the fourth quarter of 2026.
Johnson & Johnson reports at least 72% PASI 90 after two years
Johnson & Johnson released new two-year data for its oral psoriasis drug, ICOTYDE, showing at least 72% PASI 90 response rates up to week 112. This extended follow-up data from the ICONIC-LEAD trial provides crucial long-term durability information, especially as competitor Alumis Inc. prepares to submit its oral TYK2 inhibitor envudeucitinib for FDA approval in late 2026. The safety profile of ICOTYDE remained consistent with no new signals identified.
Alumis reports 48-week psoriasis symptom data
Alumis Inc. released additional 48-week Phase 3 data for its psoriasis treatment, envudeucitinib, showing significant improvements in scalp disease, itch, and quality of life for continuously treated patients. Over 80% achieved clear or almost clear scalps, and nearly 80% sustained clinically meaningful itch reduction. The company plans to submit a U.S. drug application in Q4 2026, supported by a cash runway extending into Q4 2027.
Alumis reports strong Phase 3 data for envudeucitinib, showing rapid, lasting relief in moderate-to-severe psoriasis.
Alumis Inc. announced positive Phase 3 results for its oral TYK2 inhibitor, envudeucitinib, for moderate-to-severe plaque psoriasis, demonstrating significant improvements in skin clearance, itch relief, and quality of life. The ONWARD program showed a 54% complete skin clearance rate at 48 weeks, the highest among oral therapies. Alumis plans to submit a New Drug Application (NDA) in Q4 2026, aiming to provide a leading oral treatment option.
Alumis Reports Positive Phase 3 ONWARD Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis, Advances Toward 2026 NDA Filing
Alumis Inc. announced positive Phase 3 ONWARD clinical data for envudeucitinib, an oral TYK2 inhibitor, showing high skin clearance rates and significant improvements in psoriasis symptoms. The drug achieved a 54% PASI 100 response rate at Week 48, with sustained efficacy in difficult-to-treat areas like the scalp and rapid itch relief. Alumis plans to submit a New Drug Application (NDA) for envudeucitinib in the fourth quarter of 2026, positioning it as a potential leading oral therapy for moderate-to-severe plaque psoriasis.
Alumis presents new psoriasis drug data, plans late 2026 filing By Investing.com
Alumis Inc. presented new Phase 3 clinical trial data for its psoriasis drug, envudeucitinib, showing significant skin clearance and itch reduction in patients with moderate-to-severe plaque psoriasis. The data indicated that 54% of patients achieved complete skin clearance at Week 48, with sustained improvements in itch and quality of life. The company plans to submit a New Drug Application for envudeucitinib in the fourth quarter of 2026.
(ALMS) Risk Channels and Responsive Allocation
The article analyzes Alumis Inc. (NASDAQ: ALMS), identifying weak near and mid-term sentiment that could challenge its long-term positive outlook. It highlights elevated downside risk and presents three AI-generated institutional trading strategies tailored to different risk profiles. The analysis includes multi-timeframe signal strengths, support, and resistance levels for ALMS.
H.C. Wainwright reiterates Alumis stock rating on TYK2 data
H.C. Wainwright maintained a Buy rating and a $15.00 price target for Alumis Inc. (NASDAQ:ALMS) after the full LATITUDE Atlas trial results for zaso, a TYK2 inhibitor. The trial demonstrated zaso's superior efficacy compared to Sotyktu in treating psoriasis, suggesting a significant advancement in TYK2 inhibition. Despite positive trial data, Alumis shares have declined, and the company also recently reported that its Phase 2b trial for Envudeucitinib in systemic lupus erythematosus failed to meet its primary and secondary endpoints, leading to analyst downgrades for that program.
H.C. Wainwright reiterates Alumis stock rating on TYK2 data By Investing.com
H.C. Wainwright has reiterated a Buy rating and a $15.00 price target for Alumis Inc. following positive full LATITUDE Atlas trial results for its drug zaso, which demonstrated statistical superiority over Sotyktu. Despite positive trial data, Alumis shares have significantly declined over the past six months, and the company is burning through cash. Other analysts have had mixed reactions, with some downgrading the stock after its Phase 2b trial for systemic lupus erythematosus failed to meet endpoints, while Cantor Fitzgerald maintained an Overweight rating.
Behavioral Patterns of ALMS and Institutional Flows
This article analyzes Alumis Inc. (NASDAQ: ALMS) using AI models to identify behavioral patterns and institutional flows. It highlights weak near and mid-term sentiment, posing a challenge to a long-term positive outlook, and provides three distinct institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging, along with a multi-timeframe signal analysis. The report notes elevated downside risk due to the absence of additional long-term support signals.
ALMS Stock Clocks Worst Day After 57% Drop — What Drove The Selloff?
Alumis Inc. (ALMS) shares plummeted 57% after its Phase 2b LUMUS trial for envudeucitinib in moderate-to-severe systemic lupus erythematosus missed primary endpoints. Despite the overall trial failure, a subgroup analysis showed "highly compelling" benefits, leading the company to plan discussions with regulators for a late-stage program. Analysts cut price targets but maintained "Buy" ratings, citing the potential for the lupus drug in a specific patient group and the high probability of approval for envudeucitinib in plaque psoriasis, which is still on track for Q4 U.S. filing.
Alumis Inc. (ALMS) Discusses Phase IIb LUMUS Trial Results and Subgroup Insights in Type 1 Interferon-Driven Diseases - Slideshow (NASDAQ:ALMS) 2026-09-04
Alumis Inc. (ALMS) has published a slide deck detailing the results and subgroup insights from its Phase IIb LUMUS trial for Type 1 Interferon-Driven Diseases. The article, written by SA Transcripts, highlights the company's discussion of these significant findings. This release is part of Alumis Inc.'s ongoing efforts to share developments with investors and the public.
Alumis (NASDAQ: ALMS) director buys 986K shares, agrees to give back trade profit
Alumis director Srinivas Akkaraju reported net purchases of 890,590 shares of ALMS stock in early September 2026 through affiliated funds, with total purchases of 986,721 shares and sales of 96,131 shares. A significant detail is that certain sales and purchases on September 8, 2026, were matchable under Section 16(b), resulting in short-swing profit liability, which Akkaraju has agreed to disgorge to Alumis. The transactions involved weighted average prices and did not indicate a Rule 10b5-1 trading plan.
Alumis Insider Bought Shares Worth $10,726,255, According to a Recent SEC Filing
An insider at Alumis Inc. recently purchased shares valued at $10,726,255, as disclosed in a recent SEC filing. This transaction follows several analyst adjustments to Alumis's ratings and price targets, often in response to trial data for its lupus drug, envudeucitinib. The company is a late-stage biopharmaceutical firm focusing on developing targeted therapies for immune-mediated diseases.
Alumis director Akkaraju buys $5.8m, sells $1m of ALMS shares
Alumis Inc. director Srinivas Akkaraju conducted significant transactions in early September 2026, acquiring over $10.7 million in ALMS shares and selling shares valued at more than $1 million. These trades, executed indirectly through investment funds, resulted in short-swing profit liability which Mr. Akkaraju has agreed to disgorge. The transactions occurred while ALMS shares traded significantly below their 52-week high, and amidst recent negative news regarding the company's lupus drug trial.
Alumis at Cantor conference: psoriasis strength, lupus setback
Alumis presented at the 12th Annual Cantor Fitzgerald Global Healthcare Conference, highlighting strong psoriasis data for its TYK2 drug envudeucitinib, which could lead to a near-term NDA filing. However, its Phase IIb lupus trial missed its primary endpoint in the overall population, though a robust response was observed in patients with a type I interferon signature. The company is now evaluating capital allocation, potential partnerships, and pipeline positioning following these mixed results, with shares reacting to the news by falling in regular trading but rising after hours.
Price-Driven Insight from (ALMS) for Rule-Based Strategy
This article analyzes Alumis Inc. (ALMS) using AI models, highlighting weak near and mid-term sentiment despite a long-term positive outlook. It provides three institutional trading strategies (Position, Momentum Breakout, Risk Hedging) with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal strengths, support, and resistance levels for ALMS.
Alumis to Participate in Upcoming September Investor Conferences
Alumis Inc. announced its participation in several investor conferences in September 2026, including the Wells Fargo 21st Annual Healthcare Conference, Cantor Global Healthcare Conference, Morgan Stanley Global Healthcare Conference, and Baird 2026 Global Healthcare Conference. The company, a late-stage biopharmaceutical firm focusing on immune-mediated diseases, will feature in fireside chats and presentations at these events. Webcasts of these sessions will be available on the Alumis website.
Alumis: A Brutal Lupus Setback, But Psoriasis Still Supports Upside (NASDAQ:ALMS)
Alumis Inc. (ALMS) faces significant risk as a late-stage biotech without a commercial product, with its value largely tied to envudeucitinib, a selective TYK2 inhibitor. Despite a recent share price crash due to a lupus trial failure, the potential for envudeucitinib in psoriasis still offers upside. Future success hinges on strong clinical execution, regulatory approvals, and effective financing for commercialization.
Alumis to Participate in Upcoming September Investor Conferences
Alumis is scheduled to participate in several investor conferences in September, including the Morgan Stanley 21st Annual Global Healthcare Conference, the Cantor Fitzgerald Global Healthcare Conference, and the H.C. Wainwright 26th Annual Global Investment Conference. This provides the company with opportunities to engage with investors and present its corporate strategy and updates.
Alumis crushed by midstage lupus flop but plots path to phase 3 for TYK2 inhibitor
Alumis's TYK2 inhibitor, envudeucitinib, failed to meet its primary and secondary endpoints in a phase 2b lupus trial, causing the company's stock to drop significantly. Despite the setback, Alumis plans to advance the drug to phase 3, focusing on a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high) where efficacy was observed. The company believes this subgroup represents a significant opportunity in moderate-to-severe SLE and expects the overall development timeline to remain largely unaffected.
Alumis’ TYK2 drug fails in key lupus study
Alumis' experimental drug, envudeucitinib, failed to meet its primary and secondary endpoints in a mid-stage study for systemic lupus erythematosus (SLE), causing the company's shares to drop significantly. Despite the overall failure, the company noted "robust" positive responses in a subgroup of patients with a high interferon gene signature, which Alumis believes warrants further development. Alumis plans to discuss a path forward, including a potential Phase 3 trial, with regulators and still intends to seek U.S. approval for envudeucitinib in psoriasis by the end of 2026.
Alumis Lupus Trial Misses Main Goals, but High-Interferon Subgroup Shows Promise
Alumis's Phase II LUMUS trial for systemic lupus erythematosus (SLE) failed to meet its primary and key secondary endpoints in the overall patient population. However, a pre-specified analysis revealed clinically meaningful responses in patients with a high interferon gene signature (IFNGS-high), suggesting a potential path forward for the drug envudeucitinib. The company plans to discuss a biomarker-focused Phase III strategy with regulators.
Alumis Phase 2b lupus trial misses primary and secondary endpoints
Alumis Inc.'s Phase 2b LUMUS trial for envudeucitinib in moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall patient population. However, a prespecified subgroup of patients with a high interferon gene signature (IFNGS-high) showed compelling responses. The company plans to discuss potential Phase 3 development with regulators and remains on track to submit an NDA for envudeucitinib in psoriasis in Q4 2026.
Alumis stock tumbles 55% after lupus drug trial misses goals
Alumis Inc. (NASDAQ:ALMS) shares dropped 55% after its Phase 2b LUMUS trial for envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet its primary and secondary endpoints. While the overall trial did not show significant improvement, a prespecified subgroup of patients with high interferon gene signature (IFNGS-high) showed robust clinical responses. The company plans to discuss Phase 3 development with regulators for this specific IFNGS-high patient population.
Why Is Alumis Stock Falling Tuesday?
Alumis Inc. (NASDAQ: ALMS) stock is trading lower after the company released topline data from its Phase 2b LUMUS trial for envudeucitinib in moderate-to-severe systemic lupus erythematosus, which did not meet primary or secondary endpoints across the overall trial population. However, a prespecified subgroup analysis showed robust clinical responses in patients with a high interferon gene signature, establishing a path forward for regulatory engagement on Phase 3 development. The overall trial results were impacted by an unexpected under-representation of high signature patients, who typically respond more favorably to targeted interferon therapies.
ALMS Stock Slides As Losses Mount Despite Strong Cash
Alumis Inc. (ALMS) shares have fallen significantly from late-August highs, indicating cooling market momentum and concerns over mounting losses despite the company's strong cash reserves. While ALMS has a robust balance sheet with over $500M in cash and low debt, its profitability remains deeply negative with a high price-to-sales ratio, suggesting a rich valuation. The stock's volatility makes it appealing for short-term traders, but its speculative nature demands careful planning and risk management.
Alumis Shares Plummet 59% After Lupus Study Failure Wipes Out $1.67 Billion
Alumis shares plunged 59% after its key lupus trial, LUMUS, failed to meet its primary and secondary endpoints, wiping out $1.67 billion in market value. The trial results showed no statistically significant improvement over placebo, although subgroup analysis suggested potential efficacy in IFNGS-high patients. Despite the setback, Alumis plans to discuss Phase 3 development with regulators, and its lead candidate, envudeucitinib, is still being pursued for psoriasis.
Alumis (ALMS) Could Be 33% Undervalued On Positive Psoriasis Study Results
Alumis (ALMS) stock is potentially 33% undervalued following positive topline results from its ONWARD3 extension study for envudeucitinib in psoriasis. Despite recent net losses, the company shows strong long-term momentum with a 399.38% 1-year total shareholder return. Alumis trades at a price-to-book ratio of 6.9x, which is below the peer average but above the broader US Pharmaceuticals sector, indicating a potential discount relative to close competitors while still reflecting higher expectations compared to the wider industry.
Alumis (NASDAQ:ALMS) Shares Down 7.9% - What's Next?
Alumis Inc. (NASDAQ:ALMS) shares dropped 7.9% during mid-day trading to $22.1050, following a reported adjusted loss of $1.11 per share and revenue of $1.66 million, both missing analyst expectations. Despite the poor quarterly results and recent insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $40.30, significantly above the current trading price. The company's stock performance shows a market capitalization of $2.83 billion and a negative P/E ratio, while institutional investors have increased their holdings.
Alumis (ALMS) Institutional Ownership 2026 $ALMS
This article details the institutional ownership of Alumis (ALMS) stock, including the number of institutional buyers and sellers, and total inflows and outflows over the last 12 months. It provides a table listing major shareholders, their shares held, market value, portfolio percentage, and quarterly changes. The report also addresses frequently asked questions about Alumis's largest shareholders and institutional buying/selling activity.
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders
Alumis Inc. reported positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib in plaque psoriasis and plans to file a U.S. FDA New Drug Application this year. However, the company also reported deepening losses in its second quarter, with revenue declining and net loss widening significantly. This highlights the company's reliance on successful drug approval and commercialization to justify its current valuation, which some analysts believe is higher than warranted by its financials.
What Alumis (ALMS)'s Envudeucitinib Phase 3 Data and Deepening Losses Means For Shareholders
Alumis Inc. reported second-quarter results with revenue of US$1.66 million and a net loss of US$142.22 million, while also announcing positive Phase 3 data for its oral TYK2 inhibitor envudeucitinib and plans for an FDA New Drug Application. The company's investment narrative is now heavily dependent on the successful approval and commercialization of envudeucitinib, with significant financial losses and dilution risks for shareholders. The article suggests Alumis may be overvalued based on current financials, urging investors to consider regulatory and cash burn risks.
Alumis Number of Employees 2026 | Employee Count & Headcount Data
Alumis, Inc. (ALMS), a Pharmaceuticals company, had approximately 257 total employees worldwide as of March 2026, according to Revelio Labs. The company's headcount has grown 17.2% from 220 employees in 2023 to 257 in 2026, though it saw a 3.4% decline year-over-year in 2026. Alumis is actively hiring, with 17 active job postings in 2026, and its workforce is predominantly located in North America, with an average salary of $223,944.
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target
H.C. Wainwright maintained a Neutral rating and a $25 price target for Alumis Inc., noting the stock's significant annual gain despite a recent weekly decline and concerns about overvaluation relative to its Fair Value estimate. The firm highlighted Alumis's focus on Sjögren’s disease and systemic lupus erythematosus as next indications, with the upcoming 3Q26 LUMUS results being crucial for future clinical support and capital allocation, especially given the challenges of SLE clinical development. Analyst sentiment for Alumis remains mixed, with a consensus Buy rating but a wide range of price targets, underscoring the importance of its upcoming Phase 2 data for envudeucitinib.
H.C. Wainwright reiterates Alumis stock rating at neutral, $25 target
H.C. Wainwright has reiterated a Neutral rating and $25.00 price target for Alumis Inc (NASDAQ:ALMS), emphasizing upcoming clinical trial results for Sjögren’s disease and systemic lupus erythematosus as critical for the stock's future, potentially opening a second therapeutic path beyond psoriasis. The firm highlights the significance of the LUMUS trial results for TYK2 inhibition in SLE, a historically challenging disease for drug development. Analysts' price targets for Alumis vary widely, reflecting divergent views on its clinical prospects, with Stifel and Cantor Fitzgerald also providing recent positive coverage ahead of the Phase 2 data release for envudeucitinib.
Venture investor’s big move: Latigo Biotherapeutics (ALMS) lands new 14.5% holder
Venture investor James B. Tananbaum, through Foresite Capital funds, has reported beneficial ownership of 9,181,328 shares, or 14.5%, of Latigo Biotherapeutics (ALMS) common stock. This significant stake was accumulated through various venture investments, including preferred stock purchases between 2022 and 2025, a convertible promissory note, and an IPO purchase. The holdings are for investment purposes, with potential for future adjustments based on market conditions, and are currently subject to a 180-day lock-up agreement and registration rights.